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The protective eﬃcacy of a subunit avian influenza virus H5 vaccine based on recombinant baculovirus expressed H5
haemagglutinin antigen and an inactivated H5N2 avian influenza vaccine combined with a marker antigen (tetanus toxoid) was
compared with commercially available inactivated H5N2 avian influenza vaccine in young ducks. Antibody responses, morbidity,
mortality, and virus shedding were evaluated after challenge with a Vietnamese clade 1 H5N1HPAI virus [A/VN/1203/04 (H5N1)]
that was known to cause a high mortality rate in ducks. All three vaccines, administered with water-in-oil adjuvant, provided
significant protection and dramatically reduced the duration and titer of virus shedding in the vaccinated challenged ducks
compared with unvaccinated controls. The H5 subunit vaccine was shown to provide equivalent protection to the other two
vaccines despite the H5 antibody responses in subunit vaccinated ducks being significantly lower prior to challenge. Ducks
vaccinated with the H5N2 marker vaccine consistently produced antitetanus toxoid antibody. The two novel vaccines have
attributes that would enhance H5N1 avian influenza surveillance and control by vaccination in small scale and village poultry
systems.
1. Introduction
Control of the H5N1 highly pathogenic avian influenza
(HPAI) epizootic in village communities in Southeast and
East Asia since 2003 has been diﬃcult. Conventional control
methods used for HPAI, including quarantine, enhanced
biosecurity, and stamping-out are often not logistically pos-
sible in these villages where nutrition and livelihoods depend
on low intensity poultry production. Use of vaccination
against H5N1 avian influenza has become an important
control tool in these settings [1]. All avian influenza control
programs have the goals of protection from diseases, inhi-
bition of further virus replication and transmission. Where
vaccination is used, clinical disease may be prevented but
ongoing surveillance is essential to monitor if the virus is still
present or circulating in the avian population [1].
Ducks and other members of the Anatidae family are
natural host species of influenza A viruses [2]. Prior to
2002, H5 or H7 subtype avian influenza viruses that were
highly pathogenic for terrestrial poultry were generally non-
or mildly pathogenic for ducks, but from late December
2002 circulating H5N1 HPAI viruses have been shown to be
highly pathogenic for farmed and wild ducks and a range of
other wild bird species [3–5]. H5N1 viruses isolated from
the H5N1 HPAI epizootic that commenced in 2003 have
shown some variation in virulence for ducks in experimental
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studies [4, 6]. In ducks challenged with 2003-2004 H5N1
viruses, some surviving ducks shed virus for a prolonged
period of up to 17 days [7]. Apparently, healthy ducks may
harbour H5N1 virus and shed virus for up to 17 days,
thus becoming a potential source of infection for other
poultry [7]. In many village communities in Southeast Asia,
ducks are reared in large numbers as an adjunct to rice
farming. In Thailand and Vietnam, spatial and statistical
analyses demonstrated a significant association between
H5N1 outbreaks the abundance of domestic ducks and rice-
cropping intensity [8]. Infected ducks in some of these flocks
were apparently healthy and did not show any disease signs,
making clinical detection diﬃcult and they were an infection
risk to other duck or chicken flocks [9]. So, long-term control
of the H5N1 panzootic in these areas may well depend on
controlling the infection in duck flocks along with other
strategies.
Recent field and experimental vaccines for HPAI in
poultry include inactivated, conventional whole virus vac-
cines [3, 10, 11]; inactivated vaccines developed using
reverse genetics [12–14]; in vitro baculovirus-expressed H5
antigen as subunit vaccines [10, 15]; in vivo vector-expressed
vaccines including recombinant fowl poxvirus [16, 17],
Newcastle Disease virus [18] or infectious laryngotracheitis
virus vectors [19]; and DNA vaccines [20]. These vaccines
have all conferred clinical protection and eliminated or
reduced viral shedding following HPAI virus challenge. Most
of these studies were carried out in chickens while those that
were tested in ducks have also shown protective eﬃcacy [12–
14].
Use of H5 vaccination in ducks complicates serological
surveillance using H5 antibody testing, as both infected and
vaccinated ducks produce antibody to H5 haemagglutinin.
Strategies to diﬀerentiate infected from vaccinated animals
(DIVA) have been considered and developed for incorpora-
tion into surveillance programs for avian influenza in poultry
[21]. In this study, we have evaluated two H5 vaccines in
ducks that could potentially be used in DIVA strategies. One
vaccine is a H5 subunit vaccine based on recombinant bac-
ulovirus expressed H5 haemagglutinin antigen. Serological
diﬀerentiation of infected from vaccinated birds could be
done by testing for antibody to viral antigens such as N1, M,
NP, or NS1. The other vaccine is an inactivated H5N2 whole
virus vaccine combined with tetanus toxoid antigen, with the
latter antigen used as a positive marker of vaccination with
this vaccine. These vaccines are compared with commercially
available inactivated H5N2 whole virus vaccine in the ability
to produce H5-specific antibody, to protect vaccinated ducks
from a Vietnamese H5N1 HPAI virus and reduce virus
shedding postchallenge.
2. Materials and Methods
2.1. Vaccines Used. The recombinant baculovirus-expressed
H5 vaccine was developed and produced at the Temasek Life
Sciences Laboratory, Singapore (TLL vaccine) as described
[22]. Briefly, three HA genes from diﬀerent H5N1 clade 2.1
virus strains were amplified by RT-PCR and the resultant
cDNAwas inserted, through promoter-controlled expression
cassettes, into baculovirus vectors before infecting insect
cells. The vaccine product was obtained from the supernatant
of infected insect cells and purified by ultracentrifugation.
The purified supernatant was titrated for haemagglutinin
(HA) activity using the method described previously [23],
and the stock solution was diluted such that the antigen
dose volume (0.2mL) contained 28 HA units per dose for
the high-dose vaccine and 24 HA units per dose for the low-
dose vaccine. The adjuvanted vaccine preparations were then
prepared by mixing the relevant H5 antigen concentration
with an equal volume of commercial, water-in-oil adjuvant
(Montanide, SEPPIC, Paris, France) to give a final dose of
0.4mL per duck.
The inactivated H5N2 whole virus vaccine with tetanus
toxoid marker antigen (TT/H5N2 vaccine) was prepared
as a small pilot batch by Intervet International (Boxmeer,
The Netherlands) using the standard H5N2 inactivated
whole virus used in their Nobilis Influenza H5 vaccine
combined with a commercial tetanus toxoid (TT) vaccine
antigen (Pfizer, Melbourne, Australia) diluted to contain a
final concentration of TT of 0.3mg total protein per dose
in the vaccine. This concentration had been shown to be
highly immunogenic in previous studies when combined
with inactivated H6N2 avian influenza virus in chickens and
ducks [24, 25].
The above vaccines were compared with a commercially
available inactivated H5N2 whole virus vaccine (Nobilis
Influenza H5 vaccine, Intervet International Boxmeer, The
Netherlands) (H5N2 vaccine). Both TT/H5N2 and H5N2
vaccines were formulated in a water-in-oil adjuvant. The
dose of these vaccines given to the ducks was 1.0mL which
is twice the dose given to chickens on the manufacturers
recommendation.
2.2. Source and Management of Ducks. The ducks used
for these studies were young hybrid Pekin ducks (Anus
platyrhynchos) from a commercial duck farm in Australia
(Luv-a-Duck Farm, Nhill, Victoria, Australia). They were
imported by air as day-old ducklings into Hong Kong
after meeting quarantine approvals and health certification
requirements in Australia. The farm of origin is free from
avian influenza, Newcastle disease, duck plague (duck virus
enteritis), and duck virus hepatitis viruses. Pre-export sero-
logical testing of the mother ducks for H5 and H7 avian
influenza viruses by haemagglutination inhibition (HI) tests
gave negative results. The ducklings were initially housed in
the Department of Microbiology Animal House, University
of Hong Kong (HKU) in pens with corn straw and wood
shavings as bedding and given access to a water tub with
continuous running water for bathing and drinking. Heat
lamps were provided for rearing the young ducklings and
they were given ad lib access to a commercial poultry
grower pellet ration. Vaccinations and blood sampling were
conducted in this animal house facility.
The ducks were transferred to the high biocontainment
BSL3+ animal house facility of the State Key Laboratory
of Emerging Infectious Diseases at HKU for the H5N1
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virus challenge. The ducks were housed as vaccine groups
in cages with absorbent bedding inside Class 3 negative-
pressure, flexible film isolators with HEPA-filtered inlet
air and exhaust air. Food and water were replenished
daily and room lighting was on a 12-hour cycle. Animals
were individually leg banded for identification. All animal
experimentation was carried out with the approval of the
institutional animal ethics committee and in compliance
with the facility biosafety requirements. Researchers wore
positive air pressure respirators and protective suits in the
BSL3+ animal facility at all times.
2.3. Experimental Design. An initial experiment was con-
ducted with the TLL vaccine using groups of young ducklings
vaccinated with either high dose TLL antigen (HD group,
5 ducks), high dose with adjuvant (HDA group, 5 ducks),
or low dose with adjuvant (LDA group, 6 ducks) compared
with mock vaccinated control group (6 ducks). For logistical
reasons, there were insuﬃcient 1 week old ducklings available
for experiment 1, so two age groups of ducklings (1 week and
3 weeks old) had to be used for this preliminary experiment
with TLL vaccine. These ducklings were randomly allocated
to the vaccine groups or mock vaccinated control group.
They were immunised subcutaneously at the nape of neck
with the vaccine (0.2mL of HA antigen stock with equal
volume of adjuvant or diluent) and a second dose of the
respective vaccine was given 3 weeks later. Four weeks after
the second vaccination H5N1 virus challenge was conducted
in BSL3+ animal house as described below.
In the preliminary experiment with the TLL vaccine the
challenge dose was based on a low dose challenge for H5N1
virus used in previous challenge studies in chickens but after
completion of experiment 1 it was decided to use the higher
H5N1 challenge dose that was more consistently used in
other challenge studies with H5N1 in chickens and ducks
using inactivated whole virus vaccines [10, 12].
In the second experiment, groups of young ducklings
were vaccinated with high dose TLL vaccine with adjuvant
(TLL HDA group, 8 ducks), TT/H5N2 vaccine (7 ducks) or
H5N2 vaccine (7 ducks) and compared with an unvaccinated
control group (7 ducks). The ducklings were immunised
subcutaneously at the nape of neck at 1 week of age, with
TLL vaccine given as a 0.4mL dose and the TT/H5N2 and
H5N2 vaccines given as a 1.0mL dose. A repeat dose of the
respective vaccine was given 3 weeks later.
As postvaccination HI antibody response to the TLL
vaccine was much weaker than for the whole virus vaccines
and the challenge was to be at a higher virus dose, an
additional higher dose of TLL vaccine (0.5mL of HA antigen
with equal volume of adjuvant) was given one week later (5
weeks of age) to this group. The H5N1 virus challenge was
conducted in the BSL3+ animal house as described below
when the birds were 9 weeks-old.
In both experiments, the ducks were individually identi-
fied by leg bands and blood samples were collected prevacci-
nation, after vaccination 1, vaccination 2 (prechallenge for
TT/H5N2 and H5N2 groups), vaccination 3 (prechallenge
for TLL group) and postchallenge. Serum samples in both
experiments were tested for H5 antibody by HI tests and in
the second experiment for antibody levels to TT by ELISA
assays as described below.
2.4. Virus Challenge Procedure. The challenge virus for both
experiments was HPAI virus A/Vietnam/1203/04 (H5N1)
(VN/1203/04), a clade 1 virus (WHO/OIE/FAO 2007),
which was isolated from a human case early in the H5N1
epizootic, had been shown to be closely related genetically
to H5N1 HPAI viruses from ducks and was shown to be
highly pathogenic for ducks. Virus stocks were available
at HKU. Preliminary titration (10-fold dilutions) of the
virus stock was conducted in 7 week-old ducklings in the
BSL3+ animal house to determine the challenge dose. The
virus was administered by eye drop (100 µL), intranasally
(100 µL) and orally (300 µL) to each bird at a titre of
107.6 EID50/mL (6 birds; dose = 107.3 EID50), 106.6 EID50/mL
(5 birds; dose = 106.3 EID50), 105.6 EID50/mL (6 birds; dose =
105.3 EID50) or 104.6 EID50/mL (4 birds; dose = 104.3 EID50).
The 104.3 EID50 dose (subsequently determined to be 21.6
duck LD50) caused mortality in all ducks within 7 days and
this was selected as the challenge dose for the initial TLL
vaccination experiment. A 10-fold higher dose (105.3 EID50
per bird), given via the same routes, was used for the second
experiment as discussed under experimental design.
In the BSL3+, animal house birds were anaesthetized
by inhalation of isoflurane before being inoculated with
500 µl VN/1203/04 virus at doses described above and were
housed in separate BSL3 flexible film isolators. In the initial
experiment, the unvaccinated controls and the LDA group
were housed in cages in two separate smaller isolators and
the HDA and HD groups were housed in cages in a larger
isolator complex linked by a connecting chamber. In the
second experiment, the unvaccinated controls and the TLL
HDA group were housed in cages in the two separate
smaller isolators and the TT/H5N2 and H5N2 groups were
housed in cages in the larger isolator complex. In the initial
TLL experiment, clinical signs and mortality were observed
daily for 11 days and swabs were collected daily from the
oropharynx and cloaca for virus culture. In the second
challenge study, clinical signs and mortality were observed
daily for 10 days and oropharyngeal and cloacal swabs were
collected on alternate days for virus culture. Blood was
collected from surviving birds at the end of both challenge
studies to measure H5 antibody titres and for the second
experiment to measure TT antibody levels.
Ducks dying after challenge in the second experiment
were subjected to postmortem examination to observe
the gross and histopathology changes after challenge with
a Vietnamese H5N1 HPAI virus. Pathological examina-
tion, including immunoperoxidase staining of tissues from
aﬀected ducks, was conducted as described [3, 5].
2.5. Virus Isolation Procedures. Swab samples were collected
into 1.0mL aliquots of tissue culture medium 199 containing
antibiotics (penicillin G (2 × 106 U/L), polymyxin B (2 ×
106 U/L), gentamicin (250mg/L), nystatin (0.5 × 106 U/L),
ofloxacin HCl (60mg/L), and sulfamethoxazole (0.2 g/L))
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and stored at −80◦C. For virus isolation, samples were
thawed, vortexed, centrifuged and the swab eluate was
titrated in Madin Darby Canine Kidney (MDCK) cell
cultures. Preliminary titration of the Vietnam/1203/04 virus
showed that it replicated to the same titre in MDCK cells as it
did in SPF chicken embryos. Briefly, swab eluate was serially
diluted using half-log dilution in Gibco’s modified essential
medium (MEM) with 1% foetal calf serum using a 96-well
microtitre plate. Each virus dilution was then transferred
in quadruplicate to a 96-well MDCK confluent cell plate,
with added 1% foetal calf serum in MEM. Cell cultures were
incubated at 37◦C for 3-4 days and examined daily for a
cytopathic eﬀect. The endpoint titres expressed as 50% tissue
culture infective doses (TCID50) were determined [26].
2.6. Serological Procedures. Measurement of H5 antibody
levels was conducted using the HI test procedure as described
in the WHO Manual on Animal Influenza Diagnosis and
Surveillance [27]. Briefly, 0.1mL of test sera were incubated
overnight at 37◦C with an equal volume of commercial
receptor destroying enzyme (RDE) and heat inactivated
(56◦C for 30 minutes) before further dilution to give a
final 1 : 10 dilution. The sera were added to a 96-well
microtitre plate and serially two-fold diluted, then incubated
with 4 haemagglutinating units of inactivated H5 antigen
(VN/1203/04) for 30–45 minutes at room temperature
before the addition of 0.5% turkey red blood cells for
30 minutes incubation at room temperature. Turkey red
cells are used in this laboratory as they were found to be
more consistent and sensitive than chicken red cells. The
antibody titre was expressed as the highest dilution giving
complete inhibition of haemagglutination. Positive titres
were interpreted as inhibition of haemagglutination at a
serum dilution of 1 : 10 or greater.
Antibody to TT was measured by both a competitive
ELISA (C-ELISA) and an indirect ELISA as described
previously [25]. The antigen used for ELISA plate coating
in both tests was purified tetanus toxoid (List Biological
Laboratories, Inc., CA, USA) at optimized dilution in 0.05M
carbonate-bicarbonate buﬀer, pH 9.6. Briefly, in the C-
ELISA, after thorough wash steps (6 times) in phosphate
buﬀered saline pH 7.6/0.05% v/v Tween 20 (PBST), sequen-
tially, duck sera diluted 1 : 10 in PBST/4% skim milk powder,
then goat antitetanus toxoid antibody (Accurate Chemical &
Scientific Corp., NY, USA) diluted 1 : 3200 in PBST/4% skim
milk powder, then HRP conjugated chicken antigoat IgG
diluted 1 : 20000 in PBST/4% skim milk powder (Chemicon,
CA, USA) was incubated in washed plates for 60 minutes at
37◦C. In the indirect ELISA, sequentially, duck sera at 1 : 200
dilution in PBS/4% skim milk powder, then mouse antiduck
IgY antibody goat (SeroTec, UK) diluted 1:250 in PBS/4%
skim milk powder, then HRP conjugated goat antimouse
IgG (Santa Cruz Biotechnology, USA) diluted 1 : 20000 in
PBS/4% skim milk powder was incubated in washed plates
for 60 minutes at 37◦C. After final washing in both tests TMB
substrate (TMB One Solution, Promega Corp., WI, USA)
was added for 5 minutes and stopped with 2M sulphuric
acid and plates were read in read at 450 nm with 630 nm
reference wavelength using a spectrophotometer (Dynex
MRX II, Chantilly, VA, USA). Each plate included 8 replicates
of negative control and duplicates of positive control sera
from 4 ducks that had been vaccinated with 2 doses of
commercial tetanus toxoid vaccine. In the C-ELISA the level
of TT-specific antibodies was calculated using the formula:
% Inhibition = 100 − [100× (Mean OD test serum/Mean
OD negative control serum)]. The cut-oﬀ, as determined
previously [25] was 30% inhibition.
In the indirect ELISA the antibody level was reported as
a percentage of the positive = 100 × (mean OD test-mean
OD negative)/(mean OD positive-mean OD negative). The
cut-oﬀ was based on mean + 3 × standard deviations of 50
negative ducks (1 to 9 weeks-old) and calculated to be 18.5%
of mean OD positive control.
2.7. Statistical Analysis. The geometric mean titre (GMT)
of the level of virus shed via cloaca and oropharynx from
individual birds in each group was determined for consec-
utive days postchallenge and compared between groups by
ANOVA. In groups where deaths occurred the GMT was
determined for the remaining group members. The GMT of
H5 HI antibody responses and the ELISA antibody responses
to TT antigen were compared within and between groups
pre- and postvaccination and pre- and postchallenge by
ANOVA
3. Results
3.1. Protection from Disease by the Vaccines. In the prelimi-
nary study with the TLL vaccine at lower challenge dose, mild
clinical signs of ocular discharge were noticed on day 2 and
by day 3; mild ocular discharge or conjunctivitis was evident
in 5/6 control and 5/5 HD ducks but only 1/6 LDA and 1/5
HDA ducks. Also by day 3 control ducks started to become
depressed, unkempt with reduced grooming, and reduced
interest in feed; one developed neurological signs (head tilt,
head shake, tremors) and was found dead on day 4; another
had neurological signs on day 5 and was euthanized; two
others on day 7 and another on day 8 were moribund and
were euthanized. The remaining control duck was observed
with a mild head tilt on day 8 but continued to feed until the
end of experiment on day 11. One HD duck was found dead
on day 7. All HDA (5) and LDA (6) ducks and the other HD
(4) ducks were healthy, active, alert and consuming feed until
the completion of the experiment (Table 1).
In the second phase of the study, with TLL HDA,
H5N2/TT and H5N2 vaccinated birds and controls given
the higher challenge dose, signs of ocular discharge were
noticed on day 1 in a couple of control ducks and by
day 2, 4/7 control birds had mild to copious eye discharge
while only mild discharge was present in 1/8 TLL HDA
vaccinated duck and in 1/7 H5N2 vaccinated birds. Two
controls were found dead on day 2 and 3, respectively; one
other showed neurological signs and another had a swollen,
oedematous head on day 4 and both were found dead on
day 5; two others developed mild ataxia and incoordination
and another developed conjunctivitis on day 5, one of these
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Table 1: Eﬃcacy of TLL H5 vaccine in ducks challenged with avian influenza virus [A/VN/1203/04 (H5N1)].
Vaccine group1 Challenge
dose
(EID50)
Morbidity2
Mortality2
(Mean time to
death)
HI serology3 Virus isolation-
oropharyngeal4
Virus isolation-
cloacal4
Prechallenge
No. > HI 10
(GMT > HI 10)
Postchallenge
No. > HI 10
(GMT > HI 10)
Day 2 Day 4 Day 2 Day 4
Control 104.3 1/62 5/6 (6 days) 0 1 (320) 4/6 (2.27) 6/6 (3.66) 0/6 0/5
TLL H5
High-dose
104.3 0/5 1/5 (day 7) 0 4 (452) 1/5 (0.42) 3/5 (1.87) 0/5 0/5
TLL H5
Low-dose
adjuvant
104.3 0/6 0/6 0 5 (184) 0/6 0/6 0/6 0/6
TLL H5
High-dose
adjuvant
104.3 0/5 0/5 2 (14) 3 (508) 0/5 0/5 0/5 0/5
1The TLL vaccine was given as 2 doses at 3 weeks interval with challenge 4 weeks later. Challenge was with 104.3 EID50 of the H5N1 virus.
2Number aﬀected/total challenged. Morbidity refers to neurological signs of head tilt, ataxia and weakness.
3Haemagglutination inhibition (HI) test results using A/VN/1203/04 (H5N1) antigen showing the number of ducks positive with HI titre > 10 and the
geometric mean titre (GMT) for the positive ducks is shown in parenthesis.
4Number shedding virus/number alive at each time point. Values in parenthesis are mean viral titres expressed in log10 TCID50/mL.
becamemore severely ataxic although continuing to feed and
was euthanized on day 9 and the remaining 2 control ducks
had continued to feed but had neurological signs including
incoordination and head tilt on day 10 when they were
euthanized and the experiment was completed. In contrast,
none of the TLL HDA vaccinated birds died or showed
neurological disease signs, one H5N2 vaccinated duck was
found dead on day 7 and one H5N2/TT vaccinated duck was
found dead on day 8 (Table 2). The other vaccinated ducks
remained healthy, were active and alert and continued to eat
and drink.
3.2. Virus Isolation Results. In the preliminary trial with
the TLL vaccine, oropharyngeal virus shedding occurred in
control ducks from the first day and continued for 5 days.
On days 3 and 4, virus was detected from the oropharynx of
all 6 ducks at titres between 103.0 and 105.0 TCID50/mL. For
the HDA and LDA vaccine groups’ virus was detected from
the oropharynx of 1/5 or 3/6 ducks, respectively, on day 1
but not any subsequent day. In contrast for the HD group,
virus was shed intermittently from the oropharynx from 2/5
ducks from day 1 to day 4 at titres ranging from 101.79 to
103.21 TCID50/mL; and persistently from day 2 to day 7 from
one duck (that subsequently died on day 7) at titres ranging
from 102.12 to 103.37 TCID50/mL. Nonetheless, themean virus
titres in oropharyngeal swabs for the HD group remained
significantly lower (P < .05) than for the control ducks on
days 2 to 5 postchallenge. In comparison to the virus recovery
from the oropharynx, no virus could be isolated from the
cloacal swabs of any challenged ducks in this experiment.
In the comparative study with TLL HDA, H5N2 and
H5N2/TT vaccines at the higher challenge dose, virus was
detected in the oropharynx of control ducks between day 2
and day 5 at titres ranging from 103.3 to 104.6 TCID50/mL.
In comparison to the virus recovery from the oropharynx,
virus could only be sporadically isolated from the cloacal
swabs at low titre (101.9 TCID50/mL) from two control ducks,
one on day 2 and one on day 5 postchallenge. By contrast,
no virus could be detected from the oropharyngeal swabs
or cloacal swabs from any duck in the TLL HDA, H5N2
or H5N2/TT groups throughout this experiment. The virus
isolation results on day 2 and day 4 postchallenge for both
experiments are summarised in Tables 1 and 2.
3.3. H5 Antibody Responses. In the preliminary TLL vaccine
study, only 2/5 ducks from the HDA vaccine group showed
weak H5 HI antibody responses (1 : 10 and 1 : 20) against
VN/1203/04 antigen prior to challenge. None of the LDA,
HD or control ducks had detectable antibody against
VN/1203/04 prior to challenge. By day 11 postchallenge,
most vaccinated ducks (12/15) showed a greater than four-
fold increase in HI antibody titre against VN/1203/04. There
were no significant diﬀerence in H5 HI GMT between HDA,
LDA and HD groups postchallenge. The surviving control
duck showed a postchallenge titre of 1 : 320.
In the comparative study with TLL HDA, H5N2 and
H5N2/TT vaccinations, only 3/8 TLL HDA vaccinated ducks
after the second vaccination showed low H5 HI antibody
titres (1 : 10, 1 : 20 and 1 : 40) against VN/1203/04. After the
third TLL vaccination (i.e., prechallenge) 6/8 ducks showed
low (5 ducks at 1 : 10) or moderate (1 duck at 1 : 160)
antibody titres to VN/1203/04. In contrast, all 7 H5N2 and
all 7 H5N2/TT ducks had antibody to VN/1203/04 (HI
titres from 1 : 20 to 1 : 640) after two vaccinations (i.e.,
prechallenge). The H5 HI GMT for the TLL HDA group
prechallenge were significantly lower than H5N2 group (P <
.01) and the H5N2/TT group (P < .05). H5 HI antibodies
against VN/1203/04 were not detectable in control ducks
prior to challenge. After VN/1203/04 challenge, the TLL
HDA vaccine and the H5N2/TT vaccine groups showed a
greater than four-fold rise in HI GMT (TLL 1 : 16→ 1 : 160;
H5N2/TT 1 : 49→ 1 : 422) while H5N2 vaccine group showed
only a slight rise in HI GMT (1 : 119 → 1 : 160). There
were no significant diﬀerences between the postchallenge H5
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Table 2: Eﬃcacy of H5 vaccines in ducks challenged with avian influenza virus [A/VN/1203/04 (H5N1)].
Vaccine group1 Challenge
dose
(EID50)
Morbidity2
Mortality2
(Mean time to
death)
HI serology3 Virus isolation-
oropharyngeal4
Virus isolation-
cloacal4
Prechallenge
No. > HI 10
(GMT > HI 10)
Postchallenge
No. > HI 10
(GMT > HI 10)
Day 2 Day 4 Day 2 Day 4
Control 105.3 2/7 2 5/7 (4.8 days) 0 1 (2560) 7/7 (3.21) 5/5 (3.42)
1/7
(0.04)
0/5
TLL H5
High-dose
adjuvant
105.3 0/8 0/8 6 (16) 8 (160) 0/8 0/8 0/8 0/8
Inactivated
H5N2 vaccine.
105.3 0/7 1/7 (day 7) 7 (119) 6 (160) 0/7 0/7 0/7 0/7
Inactivated
H5N2 with TT
105.3 0/7 1/7 (day 8) 7 (49) 6 (422) 0/7 0/7 0/7 0/7
1 The TLL vaccine was given in 3 doses 1, 4 and 5 weeks of age, the other vaccines were given at 1 and 4 weeks of age and challenge was at 9 weeks of age with
105.3 EID50 of the H5N1 virus.
2 Number aﬀected/total challenged. Morbidity refers to neurological signs of head tilt, ataxia, and weakness.
3 Haemagglutination inhibition (HI) test results using A/VN/1203/04 (H5N1) antigen showing the number of ducks positive with HI titre > 10 and the
geometric mean titre (GMT) for the positive ducks is shown in parenthesis.
4 Number shedding virus/number alive at each time point. Values in parenthesis are mean viral titres expressed in log10 TCID50/mL.
HI GMT between TLL HDA, H5N2 and H5N2/TT vaccine
groups. The two surviving control ducks showed either an
undetectable titre (<1 : 10) or a titre of 1 : 2560. The H5
HI serology results for both experiments are summarised in
Tables 1 and 2.
3.4. TT Antibody Responses. None of the ducks in the TLL
HDA, H5N2 and H5N2/TT vaccine groups or the control
ducks had antibody to TT antigen in prevaccination serum
samples, or in subsequent prechallenge or postchallenge
samples from the TLL HDA or H5N2 vaccine groups, or
controls with either the TT C-ELISA or the TT indirect
ELISA.
In the H5N2/TT vaccine group after the first vaccination
3/7 ducks were positive in the TT C-ELISA and 1/7 ducks
was positive by TT indirect ELISA; prechallenge all ducks
were positive by TT C-ELISA and TT indirect ELISA; and
postchallenge all were positive by TT indirect ELISA but 2
ducks were negative by TT C-ELISA. The mean % inhibition
or % of mean positive controls OD, standard deviations
for the C-ELISA and the indirect ELISA, respectively, and
significance of diﬀerences at diﬀerent time points are shown
in Table 3.
3.5. Postmortem Findings. Postmortem examination of dead
control ducks from the second experiment revealed gross
lesions of congestion and haemorrhage in multiple organs.
These aﬀected organs included the lungs, heart, pancreas,
intestines, liver, spleen, kidney, and bursa. Increased peri-
cardial fluid with fibrin clots, patches of pallor in the heart
ventricle, areas of mottling and necrosis in pancreas, moist
appearance of viscera, carcass emaciation and dehydration,
and congested blood vessels in the brain were evident in some
cases.
From the histopathology examination of tissue sections,
the control ducks that died showed varying combinations
of the following changes: congestion and oedema in the
lungs; lymphohistiocytic tracheitis and necrosis of tracheal
epithelial cells in some cases; congestion and multiple small
foci of glial cell and neurone necrosis and/or multifocal
lymphohistiocytic meningo-encephalitis, with some perivas-
cular cuﬃng and gliosis in the brain; lymphohistiocytic
myocarditis and multifocal myocardial necrosis in some
cases; multifocal pancreatic necrosis; congestion and small
foci of hepatic periportal lymphocyte necrosis; congestion
and lymphoid depletion in the spleen and general viscera
congestion.
Immunoperoxidase staining for H5 HA antigen in lung,
brain, spleen, kidney, pancreas and heart sections for all
control ducks and bursa, thymus and trachea in some control
ducks confirmed the presence of H5N1 infection in these
tissues.
However, gross and histopathological examination of the
H5N2 duck that died on day 7 and the H5N2/TT duck that
died on day 8 did not show lesions that were consistent
with the above pathology that has been recorded previously
for H5N1 HPAI in ducks [5]. Both ducks had multifo-
cal ulcerative superficial pyogranulomatous proventriculitis
with presence of gram-negative cocco-bacilli, heterophil
infiltration in the spleen and multifocal mild to moderate
tubular nephrosis suggesting death from non-H5N1 causes.
Immunoperoxidase staining of lung, brain, spleen, kidney,
pancreas, heart, bursa, liver, trachea, and proventriculus
for H5 HA antigen in sections from the dead H5N2 and
H5N2/TT ducks gave uniformly negative results.
4. Discussion
The preliminary study showed that the TLL baculovirus-
expressed H5 vaccine was able to protect ducks from severe
disease and mortality following challenge from a dose of
104.3EID50 of H5N1 virus (Vietnam/1203/04), that is highly
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Table 3: Antibody responses to tetanus toxoid antigens in ducks vaccinated with H5N2/TT marker vaccine and challenged with avian
influenza virus [A/VN/1203/04 (H5N1)].
TT ELISA type
Post-vacc. 1 Post-vacc. 2 Postchallenge
Mean (Std Dev.)3 Mean (Std Dev.) Mean (Std Dev.)
TT C-ELISA 30.7% 62.4% 35.7%
(% inhibition)1 (9.5%)a (9.2%)b (17.3%)a
TT Indirect ELISA 7.7% 65.4% 67.7%
(% positive)2 (7.4%)c (28.8%)d (31.8%)d
1The positive-negative cut-oﬀ point for the TT C-ELISA is 30% inhibition [25].
2The positive-negative cut-oﬀ point for the TT indirect ELISA was 18.5% of mean OD of the positive control.
3Within the diﬀerent TT ELISA test rows, the mean results at diﬀerent times postvaccination or postchallenge with diﬀerent letter superscripts (a, b or c, d,)
are significantly diﬀerent (P < .05).
pathogenic for ducks. All ducks immunised with low-
dose or high-dose vaccines administered with water-in-oil
adjuvant were protected but eﬃcacy was lower in the ducks
immunised with high-antigen dose without adjuvant, under-
lining the role of adjuvants in inactivated avian influenza
vaccines [1]. Virus reisolation results further indicated that
the birds vaccinated with the baculovirus H5 vaccines only
excreted virus briefly and oropharyngeal virus shedding
was eliminated (for HDA or LDA groups) compared to
unvaccinated control birds.
The comparative vaccination study showed that the
TLL HDA vaccine, given as a three dose regime and the
TT/H5N2 marker vaccine (2 doses) were as eﬀectively as
commercial H5N2 avian influenza vaccine (2 doses) in
protecting ducks from severe disease and mortality follow-
ing challenge with a ten-fold higher dose (105.3EID50) of
H5N1 virus (Vietnam/1203/04). All three vaccines showed
a similar high level of eﬃcacy in preventing virus shedding
from oropharynx and cloaca compared with control ducks.
This is a considerable advantage for the control of virus
transmission from duck to duck or to other poultry species
in the field and in reducing the environmental virus load.
The prechallenge serological responses to H5 HA for the
ducks vaccinated with inactivated whole H5N2 virus and
TT/H5N2 vaccines are similar to those reported previously
with inactivated whole virus H5 vaccines [12] but the
prechallenge H5 antibody response to TLL vaccine was poor
and low levels of HI antibody was only detected in some
ducks given two or three doses of the TLL HDA vaccine.
However, despite low serum H5 antibody responses the TLL
vaccinated birds remained protected against HPAI challenge.
In both the preliminary study and in the comparative
study, TLL vaccinated ducks mounted 4-fold rise in H5
antibody titre after challenge. The TT/H5N2 group also
showed a >4-fold rise in H5 titre after challenge but the
H5N2 group did not, however there were no significant
diﬀerences in postchallenge titres between TLL, H5N2 and
TT/H5N2 vaccine groups. Other studies have reported that
despite the absence of detectable HI antibodies (<1 : 10) in
the prechallenge sera of ducks vaccinated with either of
the two lowest vaccine doses of a reverse genetics H5N3
vaccine, there was no virus shedding or disease or deaths after
challenge with a duck-lethal H5N1 virus [12].
In nature, replication of avian influenza viruses can
occur in infected ducks without significant serum antibody
response, but despite a poor antibody response, ducks
were immune and could resist virus reinfection [28, 29].
Protection in the vaccinated ducks against HPAI, despite
the absence of HI antibody titres, may be due to a priming
of duck secretory or mucosal immunoglobulins [30], or
cell-mediated immunity [31]. The lower prechallenge serum
antibody response in TLL ducks may be a function of too
low an antigen load in the vaccine for use in ducks compared
with the dose required for chickens, which has been discussed
previously [31] and recognised by the manufacturer of the
inactivated H5N2 vaccine, who advised use of 1.0mL dose
in ducks instead of the standard 0.5mL dose in chickens.
Another consideration with the baculovirus expressed H5
antigen is that possible diﬀerences in glycosylation of insect
versus avian cells may have contributed to the low H5 HI
antibody titres in vaccinated ducks.
The more frequent reisolation of H5N1 virus in chal-
lenged ducks from the oropharynx and only sporadic isola-
tion from cloacal swabs after challenge with A/VN/1203/04
H5N1 HPAI is consistent with previous studies where viral
titres shed from the trachea of ducks were higher than from
the cloaca for Eurasian H5N1 viruses since 2003 and is
believed to be related to a shift in replication eﬃciency for
the upper respiratory tract [4, 6, 32].
These challenge studies were conducted using a het-
erologous H5N1 virus strain and it could be expected
that these vaccines would remain eﬃcacious when used
in geographical areas where diﬀerent H5N1 virus clades
exist. In contrast to human influenza vaccines, vaccines for
poultry do not appear to require close antigenic homology
with the haemagglutinin protein and remain able to oﬀer
broad cross-protection against diverse field viruses. For
example, a single recombinant fowlpox-H5 vaccine was able
to clinically protect chickens from challenge by nine diﬀerent
HP H5 strains that had between 87.3 and 100% HA protein
sequence similarity with the vaccine strain [2]. In this study,
ducks were challenged with a heterologous clade 1 H5N1
virus and resisted disease and death despite only 94-95%
HA1 protein sequence similarity between vaccine and virus
strains. However, some recent clade 2.3.2 and clade 2.3.4
H5N1 viruses have shown substantial antigenic diversity
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from the contemporary H5N1 viruses [33] and the eﬃcacy
of the TLL H5 subunit and H5N2 vaccines used in this study
would need to be tested specifically against these new viruses
before use in control programmes for them.
Ducks vaccinated with the TT/H5N2 vaccine produced
TT antibody responses similar to those in ducks vaccinated
with TT/H6N2 vaccine in previous studies [25]. Antibody
responses after the initial vaccination with the TT/H5N2
vaccine were detected in more ducks by C-ELISA (3/7) than
indirect ELISA (1/7) but after second vaccination (prechal-
lenge) all ducks were TT antibody positive (prechallenge) at
similar levels of reactivity by C-ELISA and indirect ELISA.
After H5N1 challenge TT antibody responses by indirect
ELISA persisted at similar levels to prechallenge in all ducks,
but antibody levels measured by C-ELISA were reduced and
two ducks were below the test cut-oﬀ. This observation
was similar to findings with a previous study with an in-
house TT/H6N2 vaccine in Muscovy ducks where indirect
ELISA TT antibody persisted at high levels from 6 to 19
weeks postvaccination but C-ELISA results on the same
serum showed some reduction in TT antibody response [25].
Therefore, the indirect ELISA would be better for field use
to monitor TT antibody if a H5/TT marker vaccination was
being used.
While vaccination remains an important disease control
tool for avian influenza, experiences in Hong Kong, Italy,
USA and elsewhere showed that vaccination should be
part of a programme that incorporates use of quality
and eﬃcacious vaccines; quarantine, movement restriction,
depopulation and disposal of aﬀected flocks; application or
enhancement of flock biosecurity in farms and markets;
surveillance to monitor vaccine eﬃcacy as well as field virus
circulation; and public awareness on disease prevention and
control [3, 11, 34]. Success with vaccination programs for
control of H5N1 HPAI has been quite variable in poultry
in East and Southeast Asia, owing to diﬃculties such as:
administering a correct dose to individual birds that are
freely roaming and hard to catch; providing an adequate
coverage at regular intervals and being inclusive of new
hatchlings or purchased birds; maintaining cold chain in
tropical climates; observing biosecurity in a village setting;
and challenges that local manufacturers may face in ensuring
antigen yield, inactivation of killed vaccine and formulation
with adjuvants. Specific issues relating to vaccine use for
control of H5N1 HPAI includes the risk that vaccination
may allow ongoing H5N1 transmission from vaccinated but
inapparently infected birds and whether vaccine use may
promote antigenic drift and lead to H5N1 virus endemnicity
[35]. These concerns especially relate to H5N1 infection in
ducks which are more likely to survive virus infection and
produce H5 antibody levels of the same order as ducks that
are vaccinated with inactivated whole virus H5 vaccines.
The two vaccines evaluated in this study have shown
equivalent eﬃcacy to a commercial inactivated whole virus
H5N2 vaccines in ducks, but also have some additional
features that may enhance their eﬀectiveness for field use in
village poultry avian influenza control systems in developing
countries. The recombinant H5 baculovirus vaccine has
the major advantage that it does not require embryonated
chicken eggs or a high biocontainment facility for produc-
tion. It should also be relatively straightforward to alter the
H5 insert in the baculovirus to match an evolving field H5N1
virus strain. This is a subunit vaccine and after 3 doses in
this study produced only weak H5 antibody responses but
protected ducks from disease and very significantly reduced
virus shedding in H5N1 challenged ducks. The only qualifier
with this vaccine is that the third vaccine dose at higher
antigen load did produce increased H5 antibody response
and this vaccine should be used at a higher antigen dose in
ducks, whichmay induce strongerH5HI antibody responses.
Vaccinated and infected ducks developed an anamnestic
antibody response to H5 HA after challenge but because it
is a HA subunit vaccine, testing for antibody to influenza
A proteins like NP, NS1 or M does confirm the presence of
active infection and can be used as a DIVA strategy [21].
The TT/H5N2 marker vaccine is as eﬃcacious as the
commercial H5N2 vaccine and has the advantage of posi-
tively identifying vaccinated ducks. Serological surveillance
of ducks for vaccination eﬀectiveness and evidence of
virus incursion is particularly diﬃcult where accurate farm
records or physical identification of vaccinated birds (leg
or wing bands) are not available. Ducks vaccinated with
this TT/H5N2 marker vaccine could be very eﬀectively
monitored for epidemiological purposes by simple ELISA
and HI tests for TT antibody and H5 antibody, respectively.
For example, if this vaccine was the approved vaccine for the
district or region, simply testing a statistically appropriate
sample by TT ELISA would determine the eﬀectiveness of
the coverage by the approved vaccine; concurrent testing
of H5 antibody would monitor the potency of the vaccine
in the field and whether the vaccine handling, storage and
application was producing expected levels of flock immunity,
and facilitate investigation of poor vaccine responses; testing
for TT and H5 antibody during investigation of H5N1
outbreaks in vaccinated flocks would confirm that aﬀected
birds had, or had not been eﬀectively vaccinated, and if the
vaccine was not eﬀective against the new circulating antigenic
strains of the virus; and provide objective measures of risk for
H5N1 cases in the district or region based on the level of flock
immunity to allow prioritization of avian influenza control
activities. Additionally, TT/H5N2 vaccinated ducks in this
study, that were challenged with H5N1 viruses, showed sig-
nificant rises in H5 antibody titre that could provide a signal
of recent virus infection. Similar rises in H5 antibody titre
have been observed in TT/H5N2 vaccinated chickens after
challenge withH5N1HPAI (DrDeborahMiddleton, CSIRO-
AAHL, Geelong, personal communication). Field use of this
vaccine could establish normal antibody response curves
for TT and H5 antibodies in vaccinated, uninfected ducks.
Higher than expected H5 antibody titres, indicating an
anamnestic response, would then require further virological
investigation.
Extensive vaccination programs for control of H5N1
HPAI have been or are currently being conducted in
countries like Vietnam, Indonesia, China and Egypt but
outbreaks are still occurring in village poultry systems with
domestic ducks being implicated in virus persistence. The
two novel vaccines evaluated in this study show equivalent
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eﬃcacy to an existing commercial vaccine in ducks but they
oﬀer advantages for surveillance in village poultry systems in
the above counties. The baculovirus recombinant H5 vaccine
could be further developed and optimally manufactured in
standard vaccine facilities in a developing country without
the need for large scale chicken embryo culture facilities.
The TT marker can be readily incorporated into any
inactivated whole virus or subunit H5 vaccine and used in
H5 vaccination programs to provide an eﬀective positive
marker of vaccination for surveillance of the small scale and
village poultry industries. These tools are recommended for
consideration as part of vaccination control programs in
countries with ongoing problems of H5N1 HPAI control.
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